SAN DIEGO, March 14, 2022 /PRNewswire/ — Helixmith announced today that their publication, "Gene therapy for diabetic neuropathy: A randomized, placebo-controlled phase III study of VM202, a plasmid DNA encoding human hepatocyte growth factor," was one of the top-10 most-downloaded…
Paper Reporting Results from Helixmith’s Phase 3 Gene Therapy Trial for Painful Diabetic Neuropathy was One of the Top-10 Most-Downloaded Articles in Clinical and Translational Science
